Showing 3481-3490 of 5773 results for "".
- Centricity: Study Finds Zepto Precision Pulse Capsulotomy Offers Advantages Over Manual Capsulorhexis in Treating White Cataractshttps://modernod.com/news/centricy-study-finds-zepto-precision-pulse-capsulotomy-offers-advantages-over-manual-capsulorhexis-in-treating-white-cataracts/2481513/Centricity Vision announced that a
- Startup Vedere Bio II Shuts Down After Preclinical Studies Fall Shorthttps://modernod.com/news/startup-vedere-bio-ii-shuts-down-after-preclinical-studies-fall-short/2481512/About 2 years after its launch, gene therapy start-up Vedere Bio II is shutting down. The decision comes after preclinical studies did not meet targets. The announcement was made from the company’s chairman Kevin Bitterman and CEO Cyrus Mozayeni. “We had a bold mission, to d
- Endogena Therapeutics Completes Dose Escalation in the Phase 1/2a Clinical Trial of EA-2353 for the Treatment of RPhttps://modernod.com/news/endogena-therapeutics-completes-dose-escalation-in-the-phase-12a-clinical-trial-of-ea-2353-for-the-treatment-of-retinitis-pigmentosa/2481511/Endogena Therapeutics announced that the dose-escalation stage of its phase 1/2a study of EA-2353 in retinitis pigmentosa (RP) has been successfully completed. No clinically relevant or dose-limiting adverse events were identified after repeated intravitreal injections. Given the positive sa
- Sight Sciences Appoints Ali Bauerlein as Chief Financial Officerhttps://modernod.com/news/sight-sciences-appoints-ali-bauerlein-as-chief-financial-officer/2481509/Sight Sciences announced the appointment of Alison “Ali” Bauerlein as its Chief Financial Officer and Treasurer, effective April 3, 2023. “I am incredibly excited to have Ali join Sight Sciences as we scale our business and drive toward profitable growth
- TearRestore’s Thermal Mask & HylaWipe Tea Tree Eyelid Wipes Now Available at Targethttps://modernod.com/news/tearrestores-thermal-mask-hylawipe-tea-tree-eyelid-wipes-now-available-at-target/2481508/TearRestore announced that its Thermal Mask and Eyelid Wipes will now be available at Target stores nationwide and at Target.com. The Thermal Mask and Eye Wipe offer alternative options to artificial tears and are designed to directly address the
- WaveFront Dynamics Launches WaveDyn Vision Analyzerhttps://modernod.com/news/wavefront-dynamics-launches-wavedyn-vision-analyzer/2481503/WaveFront Dynamics announced the commercial launch of its aberrometry measurement system, the WaveDyn Vision Analyzer. The WaveDyn captures a video of the eye’s optical system over time (rather than just producing a single measurement). The WaveDyn Analyzer’s high resol
- Kala Pharmaceuticals Appoints Francis Mah, MD, as Chief Medical Advisorhttps://modernod.com/news/kala-pharmaceuticals-appoints-francis-mah-md-as-chief-medical-advisor/2481501/Kala Pharmaceuticals announced the appointment of Francis Mah, MD, as Chief Medical Advisor. In this new role, Dr. Mah will provide support for Kala’s clinical development and medical activities and will play a key role in interactions with eye care professionals. Dr. Mah will serve in
- Andreas C. Kühnel Appointed as Geschäftsführer Managing Director at VSY Biotechnologyhttps://modernod.com/news/andreas-c-kuhnel-appointed-as-geschaftsfuhrer-managing-director-at-vsy-biotechnology/2481500/VSY Biotechnology has announced the appointment of Andreas Christoph Kühnel as its new Managing Director. In this new role, Mr. Kühnel will be responsible for developing and expanding VSY Biotechnology’s operations on a global scale. Mr. Kühnel brings expertise and
- Staar Surgical Names Warren Foust Chief Operating Officer; Magda Michna, PhD, Chief Clinical, Regulatory and Medical Affairs Officerhttps://modernod.com/news/staar-surgical-names-warren-foust-chief-operating-officer-magda-michna-phd-chief-clinical-regulatory-and-medical-affairs-officer/2481498/Staar Surgical announced that Warren Foust has been named Chief Operating Officer, and Magda Michna, PhD, has been named Chief Clinical, Regulatory and Medical Affairs Officer. Both positions will report to Staar Surgical’s President and CEO, Tom Frinzi. “The addition of two
- Théa Open Innovation and Galimedix Partner to Develop and Commercialize GAL-101 for Ophthalmic Indicationshttps://modernod.com/news/thea-open-innovation-and-galimedix-partner-to-develop-and-commercialize-gal-101-for-ophthalmic-indications/2481497/Théa Open Innovation and Galimedix Therapeutics announced that they have signed a licensing agreement in which Galimedix will grant Théa exclusive rights for the development and commercialization of GAL-101, Galimedix’s lead disease-modifying compound, for the topical and